Carnosine decreased oxidation and glycation products in serum and liver of high-fat diet and low-dose streptozotocin-induced diabetic rats

International Journal of Experimental Pathology

Volumn 98, Issue 5, 2017, Pages 278-288

  Aydın, Abdurrahman Fatih ^a   Bingül, İlknur ^a   Küçükgergin, Canan ^a   Doğan Ekici, Işın ^b   Doğru Abbasoğlu, Semra ^a   Uysal, Müjdat ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b YEDITEPE UNIVERSITY   (Turkey)

Author keywords

advanced glycation end products; Carnosine; diabetes mellitus; oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED OXIDATION PROTEIN PRODUCT; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C 9625; CARBONYL DERIVATIVE; CARNOSINE; CHOLESTEROL; GLUTATHIONE PEROXIDASE; LACTATE DEHYDROGENASE; MALONALDEHYDE; PROTEIN CARBONYL; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTIOXIDANT; GLYCOSYLATED HEMOGLOBIN; STREPTOZOCIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; FATTY LIVER; HISTOPATHOLOGY; LACTATE DEHYDROGENASE BLOOD LEVEL; LIPID DIET; LIVER; LIVER FUNCTION TEST; LIVER WEIGHT; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CARBONYLATION; RAT; SERUM; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; ORGAN SIZE; OXIDATION REDUCTION REACTION; PATHOLOGY; PRECLINICAL STUDY; PROCEDURES; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; BLOOD GLUCOSE; BODY WEIGHT; CARNOSINE; CHOLESTEROL; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DRUG EVALUATION, PRECLINICAL; GLYCATED HEMOGLOBIN A; GLYCATION END PRODUCTS, ADVANCED; LIVER; MALE; ORGAN SIZE; OXIDATION-REDUCTION; OXIDATIVE STRESS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; STREPTOZOCIN; TRIGLYCERIDES;

EID: 85037631802     PISSN: 09599673     EISSN: 13652613     Source Type: Journal    
DOI: 10.1111/iep.12252     Document Type: Article

References (51)

1. Aldini G., Facino R.M., Beretta G. & Carini M. (2005) Carnosine and related dipeptides as quenchers of reactive carbonyl species: from structural studies to therapeutic perspectives. BioFactors 24, 77–87.
2. Baye E., Ukropcova B., Ukropec J., Hipkiss A., Aldini G. & de Courten B. (2016) Physiological and therapeutic effects of carnosine on cardiometabolic risk and disease. Amino Acids 48, 1131–1149.
3. Benzie I.F.F. & Strain J.J. (1996) The ferric reducing ability of plasma (FRAP) as a measure of ‘antioxidant power’’: the FRAP assay. Anal. Biochem. 239, 70–76.
4. Beutler E., Duron O. & Kelly B.M. (1963) Improved method for the determination of blood glutathione. J. Lab. Clin. Med. 61, 882–888.
5. Boldyrev A.A., Aldini G. & Derave W. (2013) Physiology and pathophysiology of carnosine. Physiol. Rev. 93, 1803–1845.
6. Brown B.E., Kim C.H., Torpy F.R., et al. (2014) Supplementation with carnosine decreases plasma triglycerides and modulates atherosclerotic plaque composition in diabetic apoE(-/-) mice. Atherosclerosis 232, 403–409.
7. Buege J.A. & Aust S.D. (1978) Microsomal lipid peroxidation. Methods Enzymol. 52, 302–310.
8. Capeillère-Blandin C., Gausson V., Descamps-Latscha B. & Witko-Sarsat V. (2004) Biochemical and spectrophotometric significance of advanced oxidized protein products. Biochim. Biophys. Acta 1689, 91–102.
9. De la Maza M.P., Garrido F., Escalante N., et al. (2012) Fluorescent advanced glycation end-products (ages) detected by spectro-photofluorimetry, as a screening tool to detect diabetic microvascular complications. J. Diabetes Mellitus 2, 221–226.
10. Decker E.A., Livisay S.A. & Zhou S. (2000) A re-evaluation of the antioxidant activity of purified carnosine. Biochemistry (Mosc) 65, 766–770.
11. Freedman B.L., Hicks P.J., Sale M.M., et al. (2007) A leucine repeat in the carnosinase gene CNDP1 is associated with diabetic end-stage renal disease in European Americans. Nephrol. Dial. Transplant. 22, 1131–1135.
12. Giriş M., Doğru-Abbasoğlu S., Kumral A., Olgaç V., Koçak-Toker N. & Uysal M. (2014) Effect of carnosine alone or combined with α-tocopherol on hepatic steatosis and oxidative stress in fructose-induced insulin resistant rats. J. Physiol. Biochem. 70, 385–395.
13. Goodman Z.D. (2007) Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J. Hepatol. 47, 598–607.
14. Govindaraj J. & Sorimuthu Pillai S. (2015) Rosmarinic acid modulates the antioxidant status and protects pancreatic tissues from glucolipotoxicity mediated oxidative stress in high-fat diet: streptozotocin-induced diabetic rats. Mol. Cell. Biochem. 404, 143–159.
15. Guo C., Zhang C., Li L., Wang Z., Xiao W. & Yang Z. (2014) Hypoglycemic and hypolipidemic effects of oxymatrine in high-fat diet and streptozotocin-induced diabetic rats. Phytomedicine 21, 807–814.
16. Hanasand M., Omdal R., Norheim K.B., Gøransson L.G., Brede C. & Jonsson G. (2012) Improved detection of advanced oxidation protein products in plasma. Clin. Chim. Acta 413, 901–906.
17. Hipkiss A.R. (2009) Carnosine and its possible roles in nutrition and health. Adv. Food Nutr. Res. 57, 87–154.
18. Hipkiss A.R., Brownson C. & Carrier M.J. (2001) Carnosine, the anti-ageing, antioxidant dipeptide, may react with carbonyl groups. Mech. Ageing Dev. 122, 1431–1445.
19. Hipkiss A.R., Baye E. & de Courten B. (2016) Carnosine and the processes of ageing. Maturitas 93, 28–33.
20. Janssen B., Hohenadel D., Brinkkoetter P., et al. (2005) Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CDNP1. Diabetes 54, 2320–2327.
21. Kalaz E.B., Çoban J., Aydın A.F., et al. (2014) Carnosine and taurine treatments decreased oxidative stress and tissue damage induced by D-galactose in rat liver. J. Physiol. Biochem. 70, 15–25.
22. Kawahito S., Kitahata H. & Oshita S. (2009) Problems associated with glucose toxicity: Role of hyperglycemia-induced oxidative stress. World J. Gastroenterol. 15, 4137–4142.
23. King G.L. & Loeken M.R. (2004) Hyperglycemia-induced oxidative stress in diabetic complications. Histochem. Cell Biol. 122, 333–338.
24. Lawrence R.A. & Burk R.F. (1976) Glutathione peroxidase activity in selenium–deficient rat liver. Biochem. Biophys. Res. Commun. 71, 952–958.
25. Lee Y.T., Hsu C.C., Lin M.H., Liu K.S. & Yin M.C. (2005) Histidine and carnosine delay diabetic deterioration in mice and protect human low density lipoprotein against oxidation and glycation. Eur. J. Pharmacol. 513, 145–150.
26. Li Y.G., Ji D.F., Zhong S., Lin T.B. & Lv Z.Q. (2015) Hypoglycemic effect of deoxynojirimycin-polysaccharide on high fat diet and streptozotocin-induced diabetic mice via regulation of hepatic glucose metabolism. Chem. Biol. Interact. 225, 70–79.
27. de M Bandeira S., da Fonseca L.J., da S Guedes G., Rabelo L.A., Goulart M.O., Vasconcelos S.M. (2013) Oxidative stress as an underlying contributor in the development of chronic complications in diabetes mellitus. Int. J. Mol. Sci. 14, 3265.3284
28. Mahmoud A.M., Ashour M.B., Abdel-Moneim A. & Ahmed O.M. (2012) Hesperidin and naringin attenuate hyperglycemia-mediated oxidative stress and proinflammatory cytokine production in high fat fed/streptozotocin-induced type 2 diabetic rats. J. Diabetes Complications 26, 483–490.
29. Mong M.C., Chao C.Y. & Yin M.C. (2011) Histidine and carnosine alleviated hepatic steatosis in mice consumed high saturated fat diet. Eur. J. Pharmacol. 653, 82–88.
30. Münch G., Keis R., Wessels A., et al. (1997) Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur. J. Clin. Chem. Clin. Biochem. 35, 669–677.
31. Mylorie A.A., Collins H., Umbles C. & Kyle J. (1986) Erythrocyte superoxide dismutase activity and other parameters of copper status in rats ingesting lead acetate. Toxicol. Appl. Pharmacol. 82, 512–520.
32. Nowotny K., Jung T., Höhn A., Weber D. & Grune T. (2015) Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules 5, 194–222.
33. Ohkawa H., Ohishi N. & Yagi K. (1979) Assay for lipid peroxidation in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95, 351–358.
34. Öner-İyidoğan Y., Koçak H., Seyidhanoğlu M., et al. (2013) Curcumin prevents liver fat accumulation and serum fetuin-A increase in rats fed a high-fat diet. J. Physiol. Biochem. 69, 677–686.
35. Parveen K., Khan M.R., Mujeeb M. & Siddiqui W.A. (2010) Protective effects of Pycnogenol on hyperglycemia-induced oxidative damage in the liver of type 2 diabetic rats. Chem. Biol. Interact. 186, 219–227.
36. Peters V., Riedl E., Braunagel M., et al. (2014) Carnosine treatment in combination with ACE inhibition in diabetic rats. Regul. Pept. 194–195, 36–40.
37. Pfister F., Riedl E., Wang Q., et al. (2011) Oral carnosine supplementation prevents vascular damage in experimental diabetic retinopathy. Cell. Physiol. Biochem. 28, 125–136.
38. Reznick A.Z. & Packer L. (1994) Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol. 233, 357–363.
39. Riedl E., Pfister F., Braunagel M., et al. (2011) Carnosine prevents apoptosis of glomerular cells and podocyte loss in STZ diabetic rats. Cell. Physiol. Biochem. 28, 279–288.
40. Silvares R.R., Pereira E.N., Flores E.E., et al. (2016) Combined therapy with metformin and insulin attenuates systemic and hepatic alterations in a model of high-fat diet-/streptozotocin-induced diabetes. Int. J. Exp. Pathol. 97, 266–277.
41. Skovso S. (2014) Modeling type 2 diabetes in rats using high fat diet and streptozotocin. J. Diabetes Invest. 5, 349–358.
42. Smith P.K., Krohn R.I., Hermanson G.T., et al. (1985) Measurement of protein using bicinchoninic acid. Anal. Biochem. 150, 76–85.
43. Teufel M., Saudek V., Ledig J.P., et al. (2003) Sequence identification and characterization of human carnosinase and a closely related non-specific dipeptidase. J. Biol. Chem. 278, 6521–6531.
44. Tolman K.G., Fonseca V., Dalpiaz A. & Tan M.H. (2007) Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 30, 734–743.
45. Turk Z. (2010) Glycotoxines, carbonyl stress and relevance to diabetes and its complications. Physiol. Res. 59, 147–156.
46. Uysal M., Koçak-Toker N., Doğru-Abbasoğlu S. (2015) Carnosine protection against liver injury. In: Food and Nutritional Component in Focus No. 8, Imidazole Peptides: Chemistry, Analysis, Function and Effects, pp. 510–527 (ed V.R. Preedy), Cambridge, UK: The Royal Society of Chemistry.
47. Velez S., Nair N.G. & Reddy V.P. (2008) Transition metal ion binding studies of carnosine and histidine: biologically relevant antioxidants. Colloids Surf. B. Biointerfaces 66, 291–294.
48. Wang H. & Joseph J.A. (1999) Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. Free Radic. Biol. Med. 27, 612–616.
49. Worthington V. (1993) Catalase. In: Worthington Enzyme Manual: enzymes and related biochemical, pp. 77–80 (ed V. Worthington), New Jersey: Worthington Biochem. Corp.
50. Yamano T., Nijima A., Iimori S., Tsuruoka N., Kiso Y. & Nagai K. (2001) Effects of L-carnosine on the hyperglycemia caused by intracranial injection of 2-deoxy-D-glucose in rats. Neurosci. Lett. 313, 78–82.
51. Zheng T., Shu G., Yang Z., Mo S., Zhao Y. & Mei Z. (2012) Antidiabetic effect of total saponins from Entada phaseoloides (L.) Merr. in type 2 diabetic rats. J. Ethnopharmacol. 139, 814–821.